問卷

TPIDB > Search Result

Search Result

篩選

List

73Cases

2018-07-30 - 2020-09-30

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting6Sites

Terminated1Sites

陳仁熙
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2025-02-20 - 2027-10-29

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2025-10-01 - 2028-12-31

Phase I/II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
7Sites

Recruiting7Sites

2021-03-05 - 2026-12-31

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Recruiting8Sites

2021-03-15 - 2024-10-31

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Recruiting6Sites

2019-04-01 - 2027-11-30

Phase II

Active
  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Recruiting9Sites

2025-10-01 - 2027-09-30

Phase II

Not yet recruiting
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2025-01-01 - 2030-02-01

Phase III

Active
  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Recruiting5Sites

2020-06-01 - 2024-04-30

Phase II

Completed
  • Condition/Disease

  • Test Drug

Participate Sites
3Sites

Recruiting3Sites

2019-10-01 - 2023-01-13

Phase II

A phase 2, multicenter open-label, non-randomized study of bavituximab plus pembrolizumab in patients with advanced gastric or gastroesophageal cancer who have progressed on or after at least one prior standard therapy
  • Condition/Disease

    Gastric Cancer / GastroEsophageal Cancer

  • Test Drug

    Bavituximab

Participate Sites
4Sites

Recruiting4Sites